Emanuelli and colleagues [61] reported that the main alteration in the expression of SMURF2 in prostate and breast tumors is associated with its localization, which corresponds with many reports that the decrease in the nuclear pool of SMURF2 and increase in its cytoplasmic abundance could change the SMURF2′s access to its protein substrates, which include both tumor suppressors and oncogenes. Here, SMURF2 is linked to breast neoplasm.